Shire Adds EPO-Like Product To Pipeline
This article was originally published in The Pink Sheet Daily
Deal with Warren gives Shire TPC technology, which would build off Dynepo brand.
You may also be interested in...
The company plans to launch the orphan enzyme replacement therapy within 30 days.
Singapore-based institute is also looking at dengue fever and malaria, exec says in interview with “The Pink Sheet” DAILY.
Lilly will pay up to $500 million to settle the "vast majority" of claims alleging that the company failed to adequately warn patients of risks associated with the atypical antipsychotic Zyprexa (olanzapine), the firm announced Jan. 4